Digital PCR Market - Growth Strategy Adopted Top Market Players | Industry Report 2024

According to research report the digital PCR market is projected to reach USD 6.3 billion by 2024 from USD 4.1 billion in 2019, at a CAGR of 8.8% from 2019 to 2024. The rising incidences of infectious diseases (such as HIV, tuberculosis, and malaria) and genetic disorders; continuous technological advancements in PCR technologies and the commercialization of lab-on-chip devices and microfluidics-based portable instruments; increasing investments, funds, and grants for genomic research; increasing use of biomarker profiling for disease diagnostics; and the successful completion of the Human Genome Project are expected to augment the growth of the global Digital PCR Market over the forecast period. On the other hand, the high instrument costs—especially that of dPCR—and the technical limitations of PCR are expected to limit market growth to a certain extent.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204

The major players operating in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), Takara Bio, Inc. (Japan), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (US), Fluidigm Corporation (US), bioMérieux S.A. (France), Danaher Corporation (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Eppendorf AG (Germany), Promega Corporation (US), and Analytik Jena AG (Germany).

An analysis of the market developments between 2016 and 2019 revealed that several growth strategies such as product launches; partnerships and collaborations; acquisitions; and expansions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the Digital PCR Market.

Thermo Fisher Scientific (US) is one of the leading players in the field of healthcare and life science research. The company possesses a robust product portfolio in the dPCR and qPCR segment and a strong market presence globally, with sales and distribution networks in more than 50 countries. It focuses on strengthening its market position in the Digital PCR Market through product launches, acquisitions, and partnerships. The company mainly focuses on business strategies that include launching new products and gaining approvals in order to expand its product portfolio and offer customers a wide range of dPCR and qPCR products. Thermo Fisher Scientific also launched several products, including real-time PCR assay and system. It has received regulatory approvals for several other clinical assays from respective authorities. Thermo Fisher Scientific also focuses on acquisitions as a key strategy to strengthen its market position and expand its product portfolio with advanced technology products. In 2016, the company acquired Affymetrix, Inc., (US) which enabled Thermo Fisher to leverage Affymetrix’s microarray technology for novel product development.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204

Bio-Rad Laboratories (US) is one of the leading players in the field of disease diagnostics & laboratory products. The company has a noteworthy presence in the dPCR and qPCR industry and a wide geographic presence in major markets such as the US, Germany, Japan, China, India, and Brazil. Bio-Rad is involved in the development, manufacturing, and marketing of more than 5,000 reagents, apparatuses, and laboratory instruments (including qPCR and dPCR products). The acquisition of RainDance Technologies in January 2017 enabled Bio-Rad to strengthen its position in the dPCR market by leveraging RainDance’s droplet microfluid technology for novel product development and product portfolio expansion. During 2015–2018, Bio-Rad Laboratories witnessed a steady rise in the profit margin & annual revenue of its Life Sciences segment through the commercialization of its dPCR and qPCR instruments, assays, and software. In the last three years, Bio-Rad has also launched several dPCR and real-time PCR (qPCR) products to meet the growing market demand for novel clinical diagnosis products by offering innovative products to its customers from the research and clinical field.

Digital PCR Market – Key strategy adopted by leading market players

According to research report the digital PCR market is expected to grow from USD 3.47 billion in 2017 to USD 5.31 billion by 2022, at a CAGR of 8.9% during the forecast period. The key players in the digital PCR and real-time PCR (qPCR) market focused on various strategies such as product launches and approvals; partnerships, collaborations and agreements; mergers and acquisitions; and expansions to enhance their presence in the global market. Product approvals, launches, and enhancements were the key strategies adopted by a majority of industry players to achieve growth in the dPCR and qPCR market. Several prominent dPCR and qPCR product manufacturers such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories, F. Hoffman-la Roche Ltd., QIAGEN N.V., and Takara Bio, Inc. are focused on the development and commercialization of innovative dPCR and qPCR instruments and qPCR reagents to keep pace with the ongoing industry trends and to maintain their revenue base.

Speak to Analyst: 
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=174151204

Thermo Fisher Scientific Inc. (U.S.) held the leading position in the global dPCR and qPCR market in 2016. The company possesses a robust qPCR and dPCR product portfolio that includes key brands such as the QuantStudio qPCR system, Veriti, and TaqMan reagents. The company has a strong geographic presence in more than 100 countries across the globe, with key markets in the U.S., China, Germany, and the U.K. The company mainly focuses on developing technologically advanced qPCR and dPCR products as well as reagents that are used for medical diagnostic research by clinical, pharmaceutical, industrial, and food safety laboratories. In line with this strategy, the company launched several qPCR and dPCR systems, reagents, and kits in the last three years, including QuantStudio 3 and 5, Real-time PCR system, TaqMan Assays, and qPCR MasterMixes. These product launches helped to expand the company’s existing qPCR/dPCR product portfolio and increase its revenue base in the global market. The company also adopted inorganic growth strategies such as acquisitions, collaborations, and partnerships to strengthen its position in the market. In accordance with this, in January 2016, Thermo Fisher Scientific acquired Affymetrix Inc. (a U.S.-based company and leader in providing cellular and genetic analysis products) to expand the cellular and genetic analysis product market across North America.

Bio-Rad Laboratories Inc. (U.S.) held the second position in the global dPCR and qPCR market in 2016. The company possesses a well-established brand position across the life sciences and clinical diagnostics market, which includes a broad range of technologically advanced products (including qPCR and dPCR devices). To strengthen its current position and gain a larger market share, Bio-Rad Laboratories aggressively focuses on strengthening its R&D and product manufacturing capabilities for the qPCR and dPCR market. During 2014 to 2017, the company launched several innovative qPCR and dPCR devices, including the QX200 Droplet Digital PCR (ddPCR) system, PrimePCR Droplet Digital PCR (ddPCR) Assays, and CFX Automation System II (a robotic plate-handling system), among others. Moreover, the company adopted merger and acquisition strategy to strengthen its market position and expand its product offerings. In line with this strategy, the company acquired RainDance Technologies (U.S.) in February 2017. Furthermore, the company also focuses on expanding its product distribution networks across major markets through agreements, expansions, and partnerships with key qPCR and dPCR market stakeholders.

Get Sample of the Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204  

As of 2016, some of the other players competing in this market are F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (U.S.), Agilent Technologies Inc. (U.S.), bioMérieux S.A. (France), Fluidigm Corporation (U.S.), Danaher Corporation (U.S.), and Abbott Laboratories (U.S.), among others.

Strategies Adopted by the Major Players in this Digital PCR Market

According to research report the Digital PCR Market is expected to grow from USD 3.47 billion in 2017 to USD 5.31 billion by 2022, at a CAGR of 8.9% during the forecast period.

Product Launches: Key Strategy Adopted by the Major Players in this Market

New product launches and approvals are the key growth strategies adopted by major players to strengthen their position in the global Digital PCR Market. Moreover, strategies such as partnerships, collaborations, and agreements; as well as mergers and acquisitions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global Digital PCR Market.

The key players in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluidigm Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Promega Corporation (US), Becton, Dickinson and Company (US), Meridian Bioscience, Inc. (US), and Analytik Jena AG (Germany), among others.